γδ2 T cells

Acepodia has developed a unique γδ2 T cells that are enriched to provide the added benefits of NK functions through its proprietary selection and expansion technology. The γδ2 T cells express high level of activating receptors such as CD2 and NKG2D and low level of inhibitory receptors, enhancing potency to directly kill the tumor cells and indirectly activate other immune factors against the malignancy. Unlike traditional T cell therapies, γδ2 T cells can be administered off-the-shelf and do not need to be tailored for each individual patient, allowing for a streamlined manufacturing process and broader potential use. While an attractive candidate for cell therapies, gamma delta2 T cells only represent a small fraction of circulating T cells which has greatly limited their use in the past.

Current autologous cell therapies that are generated from a patient’s own cells require weeks to prepare. Unlike most αβT cells, γδ2 T cells can be given off-the-shelf, meaning that they do not need to be tailored to an individual patient which allows for a streamlined manufacturing process and increased scalability. Moreover, γδ2 T cells can be cryopreserved so that they are ready when patients need them. Cumulatively, these benefits translate to lower costs and greater availability for patients.